Valuation
- Market cap
- 126,740,000
- Revenue TTM
- $0
- Net income TTM
- $-26,560,000
- PE ratio
- 0.00
- Forward PE
- —
- Profit margin
- 0.00%
- Debt to equity
- 0.00
Trading
- Volume
- 1,510,000
- Avg volume
- 828,104
- Day's range
- $4.09 – $4.62
- Shares out
- 27,855,000
- Stochastic %K
- 15%
- Beta
- 1.83
- Analysts
- Strong Sell
- Price target
- $26.89
Company profile
Unicycive Therapeutics, Inc., a clinical-stage biotechnology company, identifies, develops, and commercializes therapies for the treatment of kidney diseases in the United States. It develops oxylanthanum carbonate, a lanthanum-based phosphate binding agent, which is for the treatment of hyperphosphatemia in patients with chronic kidney disease on dialysis; and UNI-494, a nicotinamide ester derivative and a selective...
Show more
Unicycive Therapeutics, Inc., a clinical-stage biotechnology company, identifies, develops, and commercializes therapies for the treatment of kidney diseases in the United States. It develops oxylanthanum carbonate, a lanthanum-based phosphate binding agent, which is for the treatment of hyperphosphatemia in patients with chronic kidney disease on dialysis; and UNI-494, a nicotinamide ester derivative and a selective ATP-sensitive mitochondrial potassium channel activator, which is in Phase I clinical trial for the treatment of acute kidney injury and pre-clinical stage for the treatment of chronic kidney disease. The company was incorporated in 2016 and is headquartered in Mountain View, California.
- Industry
- Biotechnology
- Sector
- Healthcare
- Phone
- 650 351 4495
- Website
- https://unicycive.com
- Address
- 1975 West El Camino Real, Suite 204, Mountain View, United States
Latest news
No headlines yet.
